PANDEMIC - CBDC -FREEDOM - TRUTH

  Eruptive angiomatosis triggered by the #CovidVaccine : - Sudden appearance of multiple red dots all over the body ⇒ Diagnosis: erruptive cherry hemangiomatosis - Possible reason: dysregulation of the Neuropilin-1 proteins cascade, or HVV-8 reactivation Abstract We report the case of a 64-year-old north-Italian female who accessed our dermatological emergency room for the appearance of sudden multiple red dots all over his body. She referred that the rash started five days ago, three-four hours after receiving the SARS-CoV-2 mRNA vaccine second dose (Pfizer, Cominarty). She did not report any additional symptoms, The past medical history is almost silent, except for ulcerative colitis controlled without medications. She has not taken drugs in chronic nor in a discontinuous manner in the last two months. Continue here: https://pubmed.ncbi.nlm.nih.gov/34606666/

  "Herpes Zoster is possibly a condition clinicians may expect to encounter in patients receiving #CovidVaccines " A shift in the ratio of VZV-specific CD8+ cells to naïve CD8+ cells, & changes in toll-like receptors signalling might be involved Abstract The newly developed COVID-19 vaccines have established a safe profile, yet some individuals experience a wide range of adverse events. Recently, reactivation of varicella zoster virus (VZV) has been observed after administration of different COVID-19 vaccines, although causality remains a matter of debate. The aim of this systematic review was to examine the available literature and provide an overview of reported cases of VZV reactivation following COVID-19 vaccination. We identified 12 eligible articles which included 91 patients with herpes zoster (HZ) following COVID-19 vaccination. Hypertension was the main comorbidity present in 18% of patients (16/91). Additionally, 13% of patients (12/91) had an autoimmune conditi

Acute transverse myelitis following COVID-19 vaccination: Acute Transverse Myelitis Following COVID-19 Vaccination Jhih-Jian Gao   1 ,  Hung-Pin Tseng   1 ,  Chun-Liang Lin   1 ,  Jr-Shiang Shiu   2 ,  Ming-Hsun Lee   3 ,  Ching-Hsiung Liu   1 Affiliations  expand PMID:  34579245   PMCID:  PMC8470728   DOI:  10.3390/vaccines9091008 Free PMC article Abstract An increasing number of people are undergoing vaccination for COVID-19 because of the ongoing pandemic. The newly developed, genetically engineered mRNA vaccines are critical for controlling the epidemic disease. However, major adverse effects, including neuroimmunological disorders, are being attributed to this vaccine. For instance, several cases of acute transverse myelitis (ATM) after COVID-19 vaccination have been reported in clinical trials. Here, we report an exceedingly rare case of longitudinally extensive transverse myelitis (LETM), a rare subtype of ATM involving three or more vertebral segments, that occurred shortly aft

  A 42-year-old man - 7 days after receiving the 1st dose of the #Covidvaccine (AstraZeneca): pain in the left ear & facial nerve palsy ⇒ Brain MRI revealed neuroinflammation Although vaccination against Coronavirus disease-2019 (COVID-19) is still occurring, several adverse effects temporally related to these vaccines are already being reported, even if through isolated case reports. In the present study, we describe the lesions seen on magnetic resonance imaging (MRI) of three patients who developed neurological symptoms after receiving the ChAdOX1 nCoV-19 vaccine (Oxford/AstraZeneca). The first patient presented with an ischemic stroke in the posterior limb of the left internal capsule, two days after vaccination. The second patient presented with a left facial nerve palsy, seven days after vaccination. The third patient presented with myelitis, eight days after receiving the vaccine. All patients presented the symptoms after the first dose of the vaccine and did not have a his

  A 65-year-old man - 8 days after receiving the 1st dose of the #CovidVaccine (AstraZeneca): tetraparesis (weakness in all 4 limbs) ⇒ Spine MRI: spinal cord lesion, myelitis Longitudinal extensive transverse myelitis following AstraZeneca COVID-19 vaccination Alp AA Notghi ,  internal medicine trainee ,  A  Joseph Atley ,  foundation year-1 doctor ,  B  and  Mark Silva ,  consultant neurologist  C ABSTRACT Longitudinal extensive transverse myelitis (LETM) is a rare but recognised complication of vaccination. We report the case of a 58-year-old man admitted to hospital 10 days after his first AstraZeneca COVID-19 vaccination with progressive neurological symptoms and signs, and investigations and imaging consistent with LETM. This case reviews the literature and the investigative process behind excluding other diagnoses given the patient's background of pulmonary sarcoidosis. It is unique in being the first UK report of a case of LETM with a strong temporal link to COVID-19 vaccin

  Shoulder injury related to vaccine administration (SIRVA) following mRNA COVID-19 vaccination: Report of 2 cases of subacromial-subdeltoid bursitis Abstract Shoulder pain has been reported as a common side-effect after COVID-19 vaccination particularly after administration of mRNA vaccines. Although it is usually mild and self-limiting, occasionally it can become more extensive causing severe pain and marked limited range of motion. Shoulder injury related to vaccine administration has been reported following injection of other routine vaccines. In this case report, we describe 2 cases of shoulder injury related to vaccine administration due to subacromial-subdeltoid bursitis after administration of mRNA COVID-19 vaccines. Introduction As the widespread use of COVID-19 vaccination is ongoing worldwide, radiologists have become more aware of its related imaging findings. Incidental  axillary lymphadenopathy  has been among the initially recognized and widely reported post vaccination

  Subacute thyroiditis (= inflammatory thyroid disease characterised by neck pain, fever and thyroid dysfunction) after #COVIDVaccination : https://casereports.bmj.com/content/14/10/e244711.long "Clinicians should be aware of thyroid symptoms being potentially associated with the inactive SARS- CoV-2 vaccine." Abstract Viral infections have often been associated with subacute (De Quervain) thyroiditis. Rare cases of subacute thyroiditis have been reported after vaccines. Various vaccines have been developed with different techniques against SARS-CoV-2. This case report presents a rare case of subacute thyroiditis after the inactive SARS-CoV-2 virus vaccine, CoronaVac. Case presentation A 38-year-old female physician was admitted to the endocrinology outpatient clinic with reports of swelling in the neck, pain, fatigue, loss of appetite and sweating in the evening 2 weeks after being administered with the second dose of CoronaVac vaccine. The CoronaVac vaccine was administered

  A 37-year-old woman - 7 days after 1st dose of the #CovidVaccine (Johnson & Johnson): headache, myalgia & fever. 3 days later: persistent headaches & onset of left leg pain. 2 days later: vomiting episodes ⇒ Superior sagittal sinus thrombosis - She died Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US Elsa V. C. Rodriguez ,  Fatima-Zohra Bouazza ,  Nicolas Dauby ,  François Mullier ,  Stéphanie d’Otreppe ,  Patrice Jissendi Tchofo ,  Magali Bartiaux ,  Camille Sirjacques ,  Alain Roman ,  Cédric Hermans  &  Manuel Cliquennois Purpose We reported the first described post Ad26.COV2.S (Janssen, Johnson & Johnson) vaccine-induced immune thrombocytopenia (VITT) case outside US.  Case description CA young woman without any medical history presented association of deep vein thrombosis and thrombocytopenia at day 10 after vaccine injection. The patient was treated with low-molecular weight heparin at a fir

  A 51-year-old woman - 6 days after the first #Covidvaccine (AstraZeneca): fatigue & chills. A day later: acute onset of global aphasia & right sided hemiplegia ⇒ Vaccine-induced immune thrombotic thrombocytopenia related acute ischemic strokeù Vaccine-Induced Immune Thrombotic Thrombocytopenia Related Acute Ischemic Stroke Abstract Recently cases of vaccine-induced immune thrombotic thrombocytopenia (VITT) and thrombosis following the adenoviral vector vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were reported. A mechanism similar to heparin-induced thrombocytopenia was proposed with antibodies to platelet factor 4 (PF4). Vaccine related arterial thrombosis in the brain is rare but life-threatening and optimal treatment is not established. We report clinical, laboratory, imaging findings and treatment in a 51-year-old female presenting with acute left middle cerebral artery (MCA) occlusion 7 days after the first dose of ChAdOx1 nCoV-19 vac

  A 37-year-old woman - 7 days after 1st dose of the #CovidVaccine (Johnson & Johnson): headache, myalgia & fever. 3 days later: persistent headaches & onset of left leg pain. 2 days later: vomiting episodes ⇒ Superior sagittal sinus thrombosis - She died Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US Elsa V. C. Rodriguez ,  Fatima-Zohra Bouazza ,  Nicolas Dauby ,  François Mullier ,  Stéphanie d’Otreppe ,  Patrice Jissendi Tchofo ,  Magali Bartiaux ,  Camille Sirjacques ,  Alain Roman ,  Cédric Hermans  &  Manuel Cliquennois Abstract Purpose We reported the first described post Ad26.COV2.S (Janssen, Johnson & Johnson) vaccine-induced immune thrombocytopenia (VITT) case outside US.  Case description CA young woman without any medical history presented association of deep vein thrombosis and thrombocytopenia at day 10 after vaccine injection. The patient was treated with low-molecular weight heparin

  New relapse of multiple sclerosis ( #MS ) and neuromyelitis optica as a potential adverse event of #COVIDVaccination (AstraZeneca): A report of 9 cases. The vaccination triggered a new relapse with increased disability & new brain lesions. New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19 Author links open overlay panel Yara D Fragoso a Sidney Gomes b Marcus Vinicius M Gonçalves c Euldes Mendes Junior d Bianca Etelvina S de Oliveira e Cristiane Franklin Rocha f Gutemberg A Cruz dos Santos g Carlos Bernardo Tauil h Raquel Vassao Araujo d Jean Pierre S Peron i Abstract We report on nine patients (eight cases of MS and one case of NMOSD) who presented a disease relapse in close temporal association with their first AZD1222 vaccination dose against COVID-19. These patients had been stable for a median period of six years, with no evidence of disease activity and no change in their medication. After